Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
用户k7g3AjDeE8DM
1个月前
58
10
已完结
1. 系统已在2025-08-19 10:36:04对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.annonc.2024.12.008
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0923753424049871
其他信息:
出版社: Elsevier BV
作者: T.K. Choueiri; K. Penkov; H. Uemura; M.T. Campbell; S. Pal; C. Kollmannsberger; J.L. Lee; B. Venugopal; A.J.M. van den Eertwegh; S. Negrier; H. Gurney; L. Albiges; R. Berger; J.B.A.G. Haanen; V. Oyervides Juárez; B.I. Rini; J. Larkin; F. Nolè; M. Schmidinger; M.B. Atkins; Y. Tomita; B. Ellers-Lenz; J. Hoffman; R. Sandner; J. Wang; A. di Pietro; R.J. Motzer
